Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis

References

• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–1372.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Afeltra A, Alunno A, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017;16(9):911–924.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis - shaping the immunological landscape. Nat Rev Rheumatol. 2016;12(1):63–68.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015;54(12):2134–2144.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol. 2018;9:1157.
   PubMed Web of Science ®Google Scholar
• Pacini G, Cavalli G, Tomelleri A, et al. The fibrogenic chemokine CCL18 is associated with disease severity in erdheim-chester disease. Oncoimmunology. 2018;7(7):e1440929.
   PubMed Web of Science ®Google Scholar
• Tanaka Y. Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis. 2013;72(Suppl 2):ii124–127.
   PubMed Web of Science ®Google Scholar
• Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):516–528.
   PubMed Web of Science ®Google Scholar
• Schett G, Elewaut D, McInnes IB, et al. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013;19(7):822–824.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429–442.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Hayashi M, Jin Y, et al. MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. Proc Natl Acad Sci U S A. 2016;113(5):1363–1368.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Jin Y, Yorgov D, et al. Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo. Proc Natl Acad Sci U S A. 2016;113(5):1357–1362.
   PubMed Web of Science ®Google Scholar
• De Luca G, Campochiaro C, Dinarello CA, et al. Treatment of dilated cardiomyopathy with interleukin-1 inhibition. Ann Intern Med. 2018;169(11):819–820.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Pappalardo F, Mangieri A, et al. Treating life-threatening myocarditis by blocking interleukin-1. Crit Care Med. 2016;44(8):e751–754.
   PubMed Web of Science ®Google Scholar
• Tomelleri A, Cavalli G, De Luca G, et al. Treating heart inflammation with interleukin-1 blockade in a case of erdheim-chester disease. Front Immunol. 2018;9:1233.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Tomelleri A, De Luca G, et al. Efficacy of canakinumab as first-line biologic agent in adult-onset still’s disease. Arthritis Res Ther. 2019;21(1):54.
   PubMedGoogle Scholar
• Chighizola CB, Favalli EG, Meroni PL. Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol. 2014;47(1):6–16.
   PubMed Web of Science ®Google Scholar
• Biggioggero M, Favalli EG. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. Drug Dev Res. 2014;75(Suppl 1):S38–41.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Biggioggero M, Marchesoni A, et al. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014;53(9):1664–1668.
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Antivalle M, Marchesoni A, et al. Efficacy and safety of anti-TNF agents in the lombardy rheumatoid arthritis network (LORHEN). Reumatismo. 2008;60(4):290–295.
   PubMedGoogle Scholar
• Atzeni F, Bongiovanni S, Marchesoni A, et al. Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores. Joint Bone Spine. 2014;81(1):37–40.
   PubMed Web of Science ®Google Scholar
• Ingegnoli F, Favalli EG, Meroni PL. Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to TNF alpha blocking agents? A review analysis of the literature. Autoimmun Rev. 2011;10(8):460–463.
   PubMed Web of Science ®Google Scholar
• Selmi C, Kon E, De Santis M, et al. How advances in personalized medicine will change rheumatology. Per Med. 2018;15(2):75–78.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Becciolini A, Biggioggero M, et al. Is there a need for new thresholds to define remission and low disease activity by disease activity score 28 calculated with C reactive protein? Real life data from a local registry. Ann Rheum Dis. 2015;74(1):e5.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Becciolini A, Meroni PL. Change over time in the pattern of clinical response to first-line biologic drugs in patients with rheumatoid arthritis: observational data in a real-life setting. J Rheumatol. 2017;44(2):262–263.
   PubMed Web of Science ®Google Scholar
• Aga AB, Lie E, Uhlig T, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010. Ann Rheum Dis. 2015;74(2):381–388.
   PubMed Web of Science ®Google Scholar
• Favalli E, Ingegnoli F, Zeni S, et al. [HLA typing in systemic sclerosis]. Reumatismo. 2001;53(3):210–214.
   PubMedGoogle Scholar
• Favalli EG, Caporali R, Sinigaglia L, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian society for rheumatology II. Safety. Clin Exp Rheumatol. 2011;29(3 Suppl 66):S15–27.
   PubMedGoogle Scholar
• Cantini F, Niccoli L, Nannini C, et al. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum. 2016;45(5):519–532.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum. 2017;47(2):183–192.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Tanaka Y. Rheumatoid arthritis: DMARD de-escalation – let the patient guide you. Nat Rev Rheumatol. 2017;13(11):637–638.
   PubMedGoogle Scholar
• Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016;75(8):1428–1437.
   PubMed Web of Science ®Google Scholar
• Lenert A, Lenert P. Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice. Clin Rheumatol. 2017;36(1):1–8.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Pregnolato F, Biggioggero M, et al. The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. Ther Adv Musculoskelet Dis. 2012;4(4):213–223.
   PubMedGoogle Scholar
• Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug? Autoimmun Rev. 2014;13(11):1102–1108.
   PubMed Web of Science ®Google Scholar
• Ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet. 1996;347(8998):347–352.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–637.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Fallanca F, Dinarello CA, et al. Treating pulmonary silicosis by blocking interleukin 1. Am J Respir Crit Care Med. 2015;191(5):596–598.
   PubMed Web of Science ®Google Scholar
• Cavalli G, De Luca G, Dagna L. Advances in potential targeted therapies for Erdheim-Chester disease. Expert Opin Orphan Drugs. 2017;5(3):253–260.
   Web of Science ®Google Scholar
• Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8(3):266–273.
   PubMed Web of Science ®Google Scholar
• Pallavicini FB, Caporali R, Sarzi-Puttini P, et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev. 2010;9(3):175–180.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12(2):225–229.
   PubMed Web of Science ®Google Scholar
• Galli M, Antinori S, Atzeni F, et al. Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(6):1018–1028.
   PubMed Web of Science ®Google Scholar
• Tran-Duy A, Ghiti Moghadam M, Oude Voshaar MAH, et al. An economic evaluation of stopping versus continuing tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients with disease remission or low disease activity: results from a pragmatic open-label trial. Arthritis Rheumatol. 2018;70(10):1557–1564.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977.
   PubMed Web of Science ®Google Scholar
• Edwards CJ, Fautrel B, Schulze-Koops H, et al. Dosing down with biologic therapies: a systematic review and clinicians’ perspective. Rheumatology (Oxford). 2017;56(11):1847–1856.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: spacing of TNF-blocker injections in rheumatoid arthritis study). Ann Rheum Dis. 2016;75(1):59–67.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Becciolini A, Biggioggero M. Structural integrity versus radiographic progression in rheumatoid arthritis. RMD Open. 2015;1(Suppl 1):e000064.
   PubMedGoogle Scholar
• Bejarano V, Conaghan PG, Quinn MA, et al. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology (Oxford). 2010;49(10):1971–1974.
   PubMed Web of Science ®Google Scholar
• Saleem B, Keen H, Goeb V, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis. 2010;69(9):1636–1642.
   PubMed Web of Science ®Google Scholar
• van Den Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis. 2011;70(8):1389–1394.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69(7):1286–1291.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015;74(2):389–395.
   PubMed Web of Science ®Google Scholar
• Buch MH, Seto Y, Bingham SJ, et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum. 2005;52(1):42–48.
   PubMedGoogle Scholar
• Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine. 2009;76(4):350–355.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Emery P, Ferraccioli GF, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis. 2015;74(5):843–850.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Lee SJ, Curtis JR, et al. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Ann Rheum Dis. 2015;74(6):1150–1155.
   PubMed Web of Science ®Google Scholar
• Marks JL, Holroyd CR, Dimitrov BD, et al. Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy? Arthritis Care Res (Hoboken). 2015;67(6):746–753.
   PubMed Web of Science ®Google Scholar
• Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75(1):45–51.
   PubMed Web of Science ®Google Scholar
• Rech J, Hueber AJ, Finzel S, et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis. 2016;75(9):1637–1644.
   PubMed Web of Science ®Google Scholar
• van Herwaarden N, van der Maas A, Minten MJ, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. Bmj. 2015;350:h1389.
   PubMed Web of Science ®Google Scholar
• Bouman CA, van Herwaarden N, van Den Hoogen FH, et al. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial. Ann Rheum Dis. 2017;76(10):1716–1722.
   PubMed Web of Science ®Google Scholar
• Emery P, Hammoudeh M, FitzGerald O, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014;371(19):1781–1792.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis. 2016;75(1):52–58.
   PubMed Web of Science ®Google Scholar
• van Mulligen E, de Jong PHP, Kuijper TM, et al. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study. Ann Rheum Dis. 2019;78(6):746–753.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Matsubara T, Ohta S, et al. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology (Oxford). 2015;54(4):683–691.
   PubMed Web of Science ®Google Scholar
• Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74(1):19–26.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Robles M, Ximenes AC, et al. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. Ann Rheum Dis. 2015;74(3):564–568.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Franchini S, Aiello P, et al. Efficacy and safety of biological agents in adult-onset Still’s disease. Scand J Rheumatol. 2015;44(4):309–314.
   PubMed Web of Science ®Google Scholar
• Berti A, Cavalli G, Guglielmi B, et al. Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology. 2017;6(6):e1318237.
   PubMed Web of Science ®Google Scholar
• Berti A, Campochiaro C, Cavalli G, et al. Giant cell arteritis restricted to the limb arteries: an overlooked clinical entity. Autoimmun Rev. 2015;14(4):352–357.
   PubMed Web of Science ®Google Scholar
• Berti A, Cavalli G, Campochiaro C, et al. Interleukin-6 in ANCA-associated vasculitis: rationale for successful treatment with tocilizumab. Semin Arthritis Rheum. 2015;45(1):48–54.
   PubMed Web of Science ®Google Scholar
• Biggioggero M, Crotti C, Becciolini A, et al. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther. 2019;13:57–70.
   PubMed Web of Science ®Google Scholar
• Raimondo MG, Biggioggero M, Crotti C, et al. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593–1603.
   PubMed Web of Science ®Google Scholar
• Aguilar-Lozano L, Castillo-Ortiz JD, Vargas-Serafin C, et al. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J Rheumatol. 2013;40(7):1069–1073.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Amano K, Hirabayashi Y, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol. 2014;24(1):17–25.
   PubMed Web of Science ®Google Scholar
• Huizinga TW, Conaghan PG, Martin-Mola E, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2015;74(1):35–43.
   PubMed Web of Science ®Google Scholar
• Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603–608.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sung YK, Kavanaugh A, et al. Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis. 2014;73(3):595–599.
   PubMed Web of Science ®Google Scholar
• Hagen M, Englbrecht M, Haschka J, et al. Cost-effective tapering algorithm in patients with rheumatoid arthritis: combination of multibiomarker disease activity score and autoantibody status. J Rheumatol. 2019;46(5):460–466.
   PubMed Web of Science ®Google Scholar
• van Herwaarden N, Den Broeder AA, Jacobs W, et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev. 2014;9:CD010455.
   PubMed Web of Science ®Google Scholar
• Ghiti MM, Ten KPM, Vonkeman HE, et al. Impact of stopping tumor necrosis factor inhibitors on rheumatoid arthritis patients’ burden of disease. Arthritis Care Res (Hoboken). 2018;70(4):516–524.
   PubMed Web of Science ®Google Scholar
• Dierckx S, Lauwerys B, Sokolova T, et al. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost effective in daily clinical practice: DATA from the brussels UCL RA Cohort [abstract]. Arthritis Rheumatol. 2018;70.
   Google Scholar
• Alivernini S, Peluso G, Fedele AL, et al. Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. Arthritis Res Ther. 2016;18:39.
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nair SC, Nurmohamed MT, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis. 2015;74(2):361–368.
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? Arthritis Rheum. 2011;63(4):867–870.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165–178.
   PubMed Web of Science ®Google Scholar
• van Herwaarden N, Bouman CA, van der Maas A, et al. Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis. Ann Rheum Dis. 2015;74(12):2260–2261.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Favalli EG. Cardiovascular disease in patients with rheumatoid arthritis: impact of classic and disease-specific risk factors. Ann Transl Med. 2018;6(Suppl 1):S82.
   PubMedGoogle Scholar
• Bartlett SJ, Hewlett S, Bingham CO 3rd, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis. 2012;71(11):1855–1860.
   PubMed Web of Science ®Google Scholar
• De Luca G, Cavalli G, Campochiaro C, et al. Myocarditis: an interleukin-1-mediated disease? Front Immunol. 2018;9:1335.
   PubMed Web of Science ®Google Scholar